AccScience Publishing / ITPS / Volume 2 / Issue 2 / DOI: 10.36922/itps.v2i2.545
Cite this article
19
Download
792
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
RESEARCH ARTICLE

Formulation Development and In Vitro Release Studies of Tenofovir-containing Microsponges

Ravinder Naik Eslavath1 Vasudha Bakshi2 Rajendra Kumar Jadi2,3*
Show Less
1 Department of Pharmaceutics, St. Pauls College of Pharmacy, Turkayamjal, Hayathnagar, Rangareddy, Telangana, India
2 Department of Pharmaceutics, Anurag Group of Institutions, School of Pharmacy, Hyderabad, Telangana, India
3 Department of Pharmacy, University College of Technology, Osmania University, Hyderabad, Telangana, India
INNOSC Theranostics and Pharmacological Sciences 2019, 2(2), 545 https://doi.org/10.36922/itps.v2i2.545
Submitted: 7 December 2018 | Accepted: 31 October 2019 | Published: 22 November 2019
© 2019 by the Authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC BY-NC 4.0) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Background. Microsponges are intended to carry drugs with minimum dose, while delivering beneficial effects such as better drug stability and reduced adverse effects in recipients. The present investigation was aimed to develop and characterize microsponges containing tenofovir (TNF).
Methods. Quasi-emulsion diffusion technique was used to prepare TNF-containing microsponges. Eudragit L-100 was used as a polymer, whereas glycerol and dibutylphthalates were used as plasticizers. Drug and polymer were experimented in five formulations (F1-F5) of different ratios such as 1:1, 1:2, 1:3, 1:4, and 1:5. They were characterized for various physical parameters such as size, crystallinity, and interactions.
Results. Fourier-transform infrared spectroscopic results showed that there was no incompatibility between the drug and excipients. Drug entrapment efficacy was found between 47% and 67%, and the particle size ranges were between 4.52 µm and 8.98 µm. Cumulative drug diffusion of formulation F2 (drug:polymer ratio = 1:2) was found to be 84.15% in 180 min for an X-ray diffraction studies of pure drug and microsponges formulation clearly indicated the reduction in the crystallinity of the drug which could be the reason for the improved solubility of the drug. Scanning electron microscopy analysis results indicated that the formulations have excellent structure and almost all formulations exhibited in spherical shape.
Conclusion. Based on all the evaluation parameters, formulation F2 was concluded as the best formulation, and it is an alternative approach for conventional therapy with better patient compliance.

Keywords
Microsponges
EudragitL-100
Cumulative drug release
X-ray diffraction studies
Scanning electron microscopy
References
[1]

Kapoor, A.; Sharma, R.; Sharma, P.; Gupta, P. BCS Classification System: Benchmark for Solubility and Permeability. Am. J. Pharm. Res., 2014, 4, 2233–8.

[2]

Junqueira, M.V.; Bruschi, M.L. A Review About the Drug Delivery from Microsponges. AAPS Pharm. Sci. Tech., 2018, 19, 1501–11.

[3]

Kumari, A.; Jain, A.; Hurkat, P.; Verma, A.; Jain, S.K. Microsponges: A Pioneering Tool for Biomedical Applications. Crit. Rev. Ther. Drug Carrier Syst., 2016, 33, 77–105.

[4]

Osmani, R.A.; Aloorkar, N.H.; Ingale, D.J.; Kulkarni, P.K.; Hani, U.; Bhosale, B.B.; Dev, D.J. Microsponges Based Novel Drug Delivery System for Augmented Arthritis Therapy. Saudi Pharm. J., 2015, 23, 562–72.

[5]

Kaity, S.; Maiti, S.; Ghosh, A.K.; Pal, D.; Ghosh, A.; Banerjee, S. Microsponges: A Novel Strategy for Drug Delivery System. J. Adv. Pharm. Technol. Res., 2010, 1(3), 283–90.

[6]

Won, R. Method for Delivering an Active Ingredient by Controlled Time Release Utilizing a Novel Delivery Vehicle Which Can be Prepared by a Process Utilizing the Active Ingredient as a Porogen.United States: Patent No. 4690825; 1987.

[7]

Amrutiya, N.; Bajaj, A.; Madan, M. Development of Microsponges for Topical Delivery of Mupirocin. AAPS Pharm. Sci. Tech., 2009, 10, 402–9.

[8]

Budhiraja, A.; Dhingra, G. Development and Characterization of a Novel Antiacne Niosomal Gel of Rosmarinic Acid. Drug Deliv., 2015, 22, 723–30.

[9]

Jelvehgari, M.; Siahi-Shadbad, M.R.; Azarmi, S.; Martin, G.P.; Nokhodchi, A. The Microsponge Delivery System of Benzoyl Peroxide: Preparation, Characterization and Release Studies. Int. J. Pharm., 2006, 308, 124–32.

[10]

Mahmoud, D.B.E.; Shukr, M.H., El Meshad, A.N. Gastroretentive Microsponge as a Promising Tool for Prolonging the Release of Mitiglinide Calcium in Type-2 Diabetes Mellitus: Optimization and Pharmacokinetics Study. AAPS Pharm. Sci. Tech., 2018, 19(6), 2519–32.

[11]

Kılıçarslan, M.; Baykara, T. The Effect of the Drug/Polymer Ratio on the Properties of the Verapamil HCl Loaded Microspheres. Int. J. Pharm., 2003, 252(1-2), 99–109.

[12]

Ghosh, B.; Uppalapati, Y.; Tadimarri, V.S.; Deshpannnde, K. Formulation and Evaluationn of Sitagliptinn Microsponges Using Different Polymers. Int. J. Nano Res., 2018, 1, 18–22.

[13]

Vernekar, A.; Gude, R.; Ghadi, N.; Parab, S.; Shirodker, A. Formulation and Characteization of Controlled Release Flurbiprofen Microsponges Loaded in Gels. Ind. J. Pharm. Edu. Res., 2019, 53, S50–7.

[14]

Bhatia, M.; Saini, M. Formulation and Evaluation of Curcumin Microsponges for Oral and Topical Drug Delivery. Prog Biomater., 2018, 7, 239–48.

Conflict of interest
The authors declare that they have no conflicts of interest in any kind.
Share
Back to top
INNOSC Theranostics and Pharmacological Sciences, Electronic ISSN: 2705-0823 Published by AccScience Publishing